Foresight Capital Management Advisors Inc. Buys New Position in Stryker Corporation $SYK

Foresight Capital Management Advisors Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,010 shares of the medical technology company’s stock, valued at approximately $1,058,000.

Several other large investors also recently added to or reduced their stakes in the business. Clayton Financial Group LLC purchased a new position in Stryker during the third quarter valued at approximately $26,000. United Financial Planning Group LLC purchased a new position in Stryker during the third quarter valued at approximately $27,000. Strive Asset Management LLC purchased a new position in Stryker during the third quarter valued at approximately $30,000. ANTIPODES PARTNERS Ltd purchased a new position in Stryker during the third quarter valued at approximately $34,000. Finally, Copia Wealth Management lifted its holdings in Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SYK shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Truist Financial lowered their price target on shares of Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. The Goldman Sachs Group lowered their price target on shares of Stryker from $403.00 to $357.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. TD Cowen downgraded shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price target on the stock. in a report on Monday, January 26th. Finally, William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $421.11.

Stryker Price Performance

SYK stock opened at $327.63 on Wednesday. Stryker Corporation has a one year low of $319.32 and a one year high of $404.87. The company’s fifty day moving average price is $351.94 and its 200-day moving average price is $359.01. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The company has a market capitalization of $125.48 billion, a PE ratio of 39.00, a price-to-earnings-growth ratio of 1.98 and a beta of 0.92.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the previous year, the firm earned $4.01 earnings per share. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, equities analysts anticipate that Stryker Corporation will post 14.92 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.